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EFFECTS OF BETA-BLOCKERS ON MAXIMAL OXYGEN CONSUMPTION
Steven P. Cramer, M.A.
Western Michigan University, 2003
The purpose ofthis meta-analytical review was to synthesize the data and
find a consensus within the literature as to how beta-blockers affect V02 max in the
healthy population. A thorough investigation ofthe literature was first performed,
and a coding form developed to help select those articles with similar procedures that
would be comparable to one another. This process resulted in the analysis of 10
research studies, in which the mean and standard deviation for an overall and for
correlated non beta-blocker results, selective beta-blocker results, and non-selective
beta blocker results were calculated.
The overall calculations showed little difference, but the results indicate 1
MET (3.5 mlkt l .min- 1) average decrease from the non-medicated condition to the
selective beta-blockers condition, and 1.25 MET (4.44 ml"kg-1.min- 1) decrease from
the non-medicated condition to the non-selective beta-blocker condition. These
results were deemed not to have any practical significance according to ACSM
exercise prescription guidelines. A practical difference of2 METs is considered to be
substantially important by researchers when calculating for an exercise prescription.
Though there seemed to be agreement within the literature ofthe decrease in V02
max, it is not considered to be a practical difference in the clinical setting.
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INTRODUCTION
Functional capacity, also known as V02 max, can be defined as the greatest
amount of oxygen one can utilize in strenuous activity (Brooks, et. al. 1995). There
are many factors that may have a positive influence, or negative influence in each
individual's functional capacity and plays an important role to affect health.
A positive influence on health can help to improve functional capacity. For
instance, the amount of physical training of the individual can alter functional
capacity as well as the intensity at which the training takes place. The comparison of
a middle distance runner, with an average V02 max of around 80 mr 1 .kg- 1 .min, to
that of a weight lifter with an average V02 max of around 55 �- 1 .kt 1 .min clearly
shows a greater functional capacity for the middle distance runner (McArdle, Katch,
& Katch, 1991). Likewise, a competitive runner will likely have a greater functional
capacity than a casual runner (McArdle et.al., 1991).
There are numerous factors that negatively affect functional capacity and
may increase risk-causing health problems. Smokers are also more prone to diseases
such as asthma, emphysema, cancer, and cardiovascular disease. Smoking can
reduce lung function and in turn reduce functional capacity by not allowing efficient
oxygen absorption. This occurs due to the build-up of tar that can lead to irritation of
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efficient oxygen absorption. This occurs due to the build-up oftar that can lead to
irritation ofthis tissue, asthma, or emphysema, a permanent loss ofthe alveoli and
related structures (Brooks et al. 1996). Smoking may lead to cardiovascular disease
by increasing blood pressure, heart rate, platelet adhesiveness, fatty acid
mobilization, and by decreasing high-density lipoproteins (Brooks et al. 1996).
Sedentary lifestyles may aid in the decrease in functional capacity over time, and can
potentially lead to obesity and cardiovascular disease. Development ofthese diseases
caused by the negative factors typically lead to prescribed medication. For
cardiovascular disease patients, doctors typically prescribe medications including
beta-blockers that will decrease the workload ofthe heart in order to reduce the
likelihood offurther cardiac incidence such as heart attack, congestive heart failure,
or heart arrhythmia.
Prescription ofbeta-blockers is commonly used to reduce cardiac incidence,
control hypertension, control migraine headaches, and reduce syncopal episodes
(A vailable:http://www.Medicinenet.com/script/main/art?articlekey=753 l &pf=3&tra
ck=qpa7531 [Beta blockers, n.d.]). Beta-blockers are used to control glaucoma, a
group ofeye diseases characterized by intraocular fluid pressure, producing
vasodilation and reducing the fluid pressure (Rutherforhd, Braunwald, & Cohn 1988;
Beta blockers, n.d.). Syncope, a briefloss in consciousness, is caused by a sudden
loss in blood pressure or failure ofcardiac systole (Rutherforhd et al. 1988; Beta
blockers, n.d.). Beta-blockers control cardiac asystole and prevent its occurrence
thereby controlling syncopal episodes. An individual who suffers from any ofthese
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symptoms, whether obese, sedentary, recreational athletes, or elite athletes may be
prescribed beta-blocker medications.
One of the major concerns in the elite endurance athlete population is
functional capacity and how that level can be increased (McArdle et al. 1991). Such
athletes track their training regimen very closely and can identify a decline or
improvement in their performance. Beta-blockers have been placed on the
International Olympic Committee's (IOC) list of banned substances (Brooks, et al.
1996). IOC has banned beta-blockers as an ergogenic aid that may possibly improve
the performance of the Olympic athlete and give an edge over competitors (Brooks,
et al. 1996). Svendenhag, Henriksson, Juhlin-Dannfelt, & Asano (1984) showed that
an improvement in functional capacity could be obtained in, both sedentary
individuals and athletes, when prescribed beta-blockers, although the overall effect
of beta-blockers was a reduction in VO2 max when compared to non-medicated
results. There is evidence that the time to exhaustion is decreased in subjects taking
beta-blockers (Gullistad, Hallen, Medbo, Gronnerod, Holme, & Sejersted,1996),
hindering performance. Beta-blockers decrease heart rate and blood pressure, and
also reduce functional capacity. In support of this statement, Kaiser (1982) showed a
decrease in performance in subjects taking beta-blockers. In contrast, Mori, Handa,
Terao, Kiyonaga, Shindo, Matsunaga, Sasaki, & Arakawa (1992) showed no
significant difference in functional capacity with subjects taking beta-blockers.
Maintenance of functional capacity can be somewhat explained by Scruggs, Martin,
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Broeder, Hofman, Thomas, Wambsgan, & Wilmore (1991) who showed an increase
in stroke volume compensating for a decreased heart rate.
In the field of cardiac rehabilitation numerous patients are prescribed a beta
blocker medication after a cardiac incident, and perform stress tests as part of follow
up care. Patients who were active athletes or just very active in general are not
prepared to see the reduction in their functional capacity that follows a cardiac
incident. It is not clearly explained whether this change in ability is due to the
medication or due to the cardiac incident. This raised the question of the effect beta
blockers have on V02 max, and is this effect one of practical importance in the
clinical setting? Does the literature make a clear-cut statement saying beta-blockers
have a significant effect on the reduction of functional capacity? This remains to be
seen, and therefore, the purpose of the study was to determine if there is a consensus
agreement in the literature of the effect that beta-blockers have on V02 max. What is
considered by current research to be a practical difference for individuals taking
beta-blockers? Is there practical significance that requires changing prescription of
exercise? This is important for clinicians who prescribe exercise for cardiac
rehabilitation patients taking these medications. Clinicians are responsible to make
changes to exercise prescriptions in the event that medication prescriptions change.
Cardiac patients may initially enter the program on beta-blockers and not be able to
tolerate them. In this scenario, the rehab professional needs to know if the intensity
of exercise previously prescribed for the patient will still be adequate for them, or
does it need to be increased to compensate for the absence of the beta-blocker.
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The purpose of this meta-analytic review was to determine if there is a
consensus agreement in the literature of the effect that beta-blockers have on VO2
max. This information could prove valuable to the training regimen of the elite
athlete while on beta-blocking medication. This population may use beta-blocker
medications to help control anxiety, glaucoma, or syncope. Benefit for the general
population can be gained in the knowledge that these medications may affect
exercise tolerance and reduce the level of fitness they may expect to achieve. The
rehabilitation professional may gain benefit for prescribing exercise heart rate ranges
or alter workload levels for cardiac rehabilitation patients.

REVIEW OF LITERATURE
The literature reviewed for this paper related to functional capacity,
physiological changes that take place during maximal and submaximal exercise, and
the relationship of beta-blockers on these parameters. The literature is presented
under the following topics for organizational purposes: (1) Beta-Blockers (2) Beta
Blockers and Functional Capacity, (3) Training Effect, (4) Selective and Non
Selective Beta-Blockers, (5) Effects on respiration, and (6) Summary.
Beta-Blockers
Beta Adrenergic Blockers (beta-blockers) are a class of drug that block beta
adrenergic substances such as epinephrine, a key agent in the sympathetic portion of
the autonomic (involuntary) nervous system, and in the activation of heart muscle
(Focusonheartcom, 1998). By blocking these agents, stress on the heart is reduced
through slowing of the heartbeat, reduction in the strength of contraction, and a
reduction in blood vessel constriction (Focusonheartcom, 1998). There are two major
subtypes of beta-receptors in the human body, beta-I and beta-2, which are present
in different proportions in different tissues (Rutherford, Braunwald, and Cohn,
1988). Beta-I receptors are found primarily in the heart muscle, and when

stimulated, cause an increase in heart rate, AV (atrial-ventricular) conduction, and
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1988). Beta-2 receptor stimulation results in bronchodilation and vasodilation
(Rutherford et al. 1988). Beta-blockers are therefore classified according to the
relative cardio-selectivity: non-selective beta-blockers affect both beta-I and beta-2
receptors sites, and beta-I selective blockers predominantly affect the beta-I receptor
sites (Rutherford et al. 1988). Even though heart rate is slowed and contractility of
the heart muscle is diminished with beta-blocker therapy, cardiac output will
continue to increase with increased activity due to a compensatory increase in stroke
volume (Sheffield, 1988).
Beta-blocker therapy can be utilized in treating multiple symptoms and
abnormalities. They are effectively used to treat cardiac arrhythmias or prevent
sudden death after a myocardial infarction (M. I.) (Zipes, 1988). Beta-blockers are
also used to treat angina pectoris, to decrease pain and reduce the need for analgesics
presumably by reducing ischemia through the reduction in after-load (Beta blockers,
n.d., 2003). Beta-blockers cause vasodilation and in turn reduce stress on the heart
and effectively reduce blood pressure. (Beta blockers, n.d.). Another effect of beta
blockers includes blocking reception of impulses to the sympathetic nervous system
reducing symptoms of anxiety. Beta-blockers can be used to treat migraine
headaches caused by stress and anxiety otherwise known as tension headaches, and
stage fright (social phobia) caused by anxiety. Glaucoma is caused by an imbalance
in intraocular fluid where fluid does not drain properly increasing the internal
pressure of the eye. Beta-blockers can be effective in restoring the fluid balance and
reducing the intraocular pressure. Syncope (fainting) due to cardiac systole can be a
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beta-blocker controlled arrhythmia effectively limiting this symptom (Rutherforhd,
et al. 1988; Beta blockers, n.d.). It is generally considered that no one beta-blocker
offers a distinct advantage over another, and when titrated to the proper dosage, all
can be used effectively to treat these disorders (Zipes, 1988).
Beta-Blockers and Functional Capacity
Beta-blockers are common therapy for patients who have reduced left
ventricular function, have had a myocardial infarction, or to reduce blood pressure in
hypertensive patients. They are also used to control arrhythmias and have been
shown to significantly decrease resting and exercise heart rates (Zipes, 1988). There
are a number of studies on the effects of Beta-blockers and exercise with
measurements for each study ranging from heart rate and respiratory rate to V02 max
and respiratory exchange ratio (RER). While there were little differences found with
RER and blood samples (for lactate, epinephrine and norepinephrine) in subjects
taking beta-blockers, researchers have indicated that the use of beta-blockers
increase stroke volume by prolonging ventricular fill time (Scruggs et al. 1991). This
increase in stroke volume helps to decrease after-load and reduce the workload of the
heart. An increase in stroke volume causes an increase the pre-load (ventricular
filling), or stretch mechanism on the heart that causes an increase in the strength of
contraction, but reduces the stress on the heart (Brooks et al. 1996).
All of the studies reviewed have exhibited that there has been a decrease in
heart rates, and likewise a decrease in blood pressure. Nuetel, Smith, Venkata, Ram,
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Kaplan, Papademetriou, Fagan, Leflowitz, Kazempour, & Weber (1993) indicated a
significant decrease in subject's blood pressure reporting beta-blockers' effectively
reducing hypertension by 43%- 49%. After-load, or the resistance to ventricular
emptying, is increased with hypertension (high blood pressure). This resistance
increases the workload ofthe heart (myocardium) (Brooks et al. 1996). Hughson, &
Smyth (1983) found no significant difference in oxygen consumption between data
for beta- I selective blockers, non-selective beta-blockers, and placebo with steady
state exercise between 80%-90% ofVO2 max. At 45% VO2 max, there was no
significant decrease in cardiac output for both beta- I and non-selective beta-blockers
when compared with placebo (Broeder, Thomas, martin, Hoffman, Jesek, Scruggs,
Wamsburg, & Wilmore, 1993). Reduction in exercise capacity (VO2 max) was found
in a study by Yonga, Oyuga, & Njeru (1993) in which subjects were given oral beta
blockers 90 min prior to a cycle ergometer test measuring VO2 max. Foley,
Brubaker, Matraxxo, Berry, Pribanich, & Miller (1997) indicates a 3% decrease in
peak VO2 with subjects taking beta-blockers, which he reported to be significantly
lower from measurements reported from non-medicated subjects. Cardiac output is
therefore maintained during resting conditions, but will not result in the same
increase during submaximal and maximal exercise conditions compared to placebo
(Tesch & Kaiser, 1983).
Broeder et al. (1993) found that cardiac output decreased over an extended
exercise period with higher intensities regardless ofbeta-blocker or placebo usage,
this is known as cardiac drift. Beta-blockers have also been shown to slow the
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adaptation to steady state V02 (Hughson, & Smyth, 1983 ). Hendricks &
Schipperheyn's (1983) findings with submaximal workload tests showed slightly
lower V02 response (25.4 mlkg-1.min- 1) with beta-blockers when compared to
placebo 27.6 mlkg-1.min-1, which was significant. This may lead to arguments that
beta-blockers cause a faster rate of fatigue and in turn reduce the subject's ability to
achieve a true V02 max. In agreement with this assumption, Gullistad et al. (1996)
report a 5.3% reduction in the time to exhaustion during exercise testing, following
both acute and chronic administration of non-selective beta-blockers (propanolol)
when compared to placebo. Bevilacqua, Savonitto, Bosisio, Chebat, Bertora,
Sardina, & Norbiato (1993) indicate that there is a difference in the amount of
cardiac output decrease over time comparing cardio-selective beta-1 blockers
(pindolol) and non-selective beta-blockers (propanolol). They report that pindolol
decreased cardiac output similarly to placebo while propanolol decreased more
quickly at 25% V02 max and 45% V02 max. This decrease was exhibited to be
smaller in trained subjects when compared to untrained subjects (Broeder et al.
1993). In patients with heart disease and reduced ventricular function beta-blockers
have been indicated to increase functional capacity (Genth-Zotz, Zotz, Sigmound,
Hanrath, Hartman, Bohm, Waagstein, treese, Meyer, & Darius, 2000). This is
important in treating these patients and improving their quality of life allowing them
to live more "normally" rather than being restricted by their condition.
To summarize, the research indicates that there is a decrease in functional
capacity as measured by V02 max with individuals taking beta-blockers, but is not
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clear on whether this decrease is significant or not. This decrease tends to be more
pronounced with non-selective beta-blockers. There also seems to be an indication
that at submaximal workloads, stroke volume in individuals taking beta-blockers is
increased due to an increase in ventricular fill time, and leads to maintenance of
cardiac output and maintenance of functional capacity.
Training Effect
Individuals taking beta-blockers can experience significant increases in VO2
max while engaging in a cardiovascular training program (Svendenhag, 1984). In
support ofthese findings, Sweeney, Fletcher, & Fletcher (1989) found that a training
effect could be achieved while taking beta-blockers. The researchers also compared
the effects ofbeta-1 selective blockers with the non-selective beta-blockers. The
results indicated a lower VO2 max while on non-selective beta-blockers; however,
subjects experienced an increase in VO2 max from baseline. Kaiser (1982) found
drug induced performance impairment with subjects taking beta-blockers, which was
not commensurate with the effect previously observed with exercise bradycardia.
Muscle composition studies have exhibited less change in mitochondrial
enzyme adaptation while subjects in training were taking propanolol as opposed to
placebo, indicating an increased mitochondrial enzyme activity however less
pronounced (Svedenhag, Henriksson, & Juhlin-Dannfelt, 1984). A 7% decrease in
running performance may be explained by insufficient oxygen delivery as decreased
oxygen uptake was found with the administration ofbeta-blockers (Kaiser, 1982).
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The blunted adaptation in mitochondrial enzyme activity could help to explain the
lower VO2 found in these studies, as well as the accelerated fatigue ratings. Kaiser
(1982) found that subject rating of perceived exertion (RPE) suggested a more
pronounced subjective feeling of fatigue while taking beta-blockers. He reports
values of RPE for placebo to be 4.3 ± 0.2, for propanolol 6.8 ± 0.5, and for tenormin
5.4 ± 0.3 on a 1-10 scale I being the least exertion, and 10 being the most exertion.
Exercise heart rate as well as resting heart rate has been exhibited to be significantly
lower when subjects take beta-blockers (Broeder et al.1993).
Selective and Non-Selective Beta- Blockers
The type of beta-blocker, whether beta-I selective or non-selective,
has received much attention. Propanolol, a non-selective beta-blocker, has been
indicated to produce a greater reduction in VO2 max than beta-I selective blockers.
Anderson, Wilmore, Joyner, Freund, Hartzell, Todd, & Ewy (1985) studied the
effects of propanolol (non-selective), atenolol (beta-I selective), and placebo in
highly trained runners. The subjects performed a V02 max test, submaximal V02
measures, and a timed IO K race. The results indicated a greater reduction in V02
max with propanolol vs. atenolol and placebo. Both beta-blockers exhibit a
significant decrease in all parameters including, a greater increase in IO K finish time
(slower time) and a higher RPE score at the end of the 10 K race. These results
indicate that muscular fatigue is part of the effect of beta-blockers. A decrease in
cardiac output suggests less oxygenation of the muscles, reducing the time to fatigue
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for beta-blocker trials. Gordon, VanRensburg, Russell, Kawalsky, Celliers, Celliers,
& Myburgh (1985) and Foley et. al. (1997) has suggested that beta-I selective
blockers produce less of a decrease in VO2 max measures than do non-selective. Due
to such findings, athletes requiring beta-blocker therapy should be prescribed beta-I
selective blockers rather than the non-selective type.
In contrast, Mori et al. (1992) investigated the effect of selective beta
blockers and non-selective beta-blockers on VO2 max. Subjects performed tests on a
cycle ergometer and resulted in VO2 max (mlkg-1.min-1) of 41.4 ± 3.9 for placebo,
and arotinolo� a non-selective beta-blocker, 39.4 ± 3.6. These results were
determined not to be significantly different. Ades, Gunther, Meachum, Hardy, &
Le Winter (1990) found in a IO-week training study with runners taking a placebo,
metoprolol (selective) and propanolol (nonselective), the placebo group increased
their aerobic capacity by 24 %, the metoprolol group by 8 %, and the propanolol
group had no overall change. Derman, Sims, & Noakes (1992) compared the effects
of an ACE inhibitor, a calcium channel blocker, and a beta-blocker. The findings
indicated that the ACE inhibitor produced a significantly lower decrease in VO2 max
and still had a positive effect on blood pressure, though less significant. These results
indicate that hypertensive athletes looking to maintain VO2 max would be better
served if prescribed an ACE inhibitor rather than beta-blocker due to the smaller
negative effect in functional capacity.
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Effects on Respiration
The effect of beta-blockade on ventilation and hypertension has been the
main concern of other researchers hoping to determine the cause of the decrease in
V02 max. It was previously indicated that non-select_ive beta-blockers, affecting the
beta-2 receptors, might have a hand in reducing aerobic capacity due to decreased
minute ventilation (Peterson, 1983). No evidence that beta-blockers have an affect on
ventilation causing a decreased aerobic capacity has been documented (Peterson et
al., 1983). McLeod, Knopes, Shand, & Sandeer-Williams (1985) determined that
tidal volume was decreased in the presence of beta-blocker therapy, and respiratory
frequency was increased in order to compensate for this. Foley et al (1997) also
found a decrease in tidal volume with subjects taking beta-blockers. According to
Foley et al (1997), there is essentially no change in VC02, RER, ventilation, or
respiratory rate. With these results, indicating no change in the delivery of
oxygenation of the blood during exercise with beta-blockade, it has not been found
that beta-blockers decrease the oxygen delivery system for maintaining functional
capacity.
Summary
While many researchers demonstrated evidence that beta-blockers diminish
functional capacity, there are a few studies that claim there is no significant
difference. The reduction in functional capacity can be explained by a reduction in
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cardiac output at maximal workloads coupled with a reduction in rriaximum heart
rate and heart rate response. Muscular fatigue has also played a role in the decrease
in functional capacity. Investigations into a reduction in respiration indicate no
evidence of beta-blockers having an adverse effect. Though cardiac output, heart rate
and blood pressure were all found to decrease with these medications, athletes still
achieve a training effect and see improvements in performance while on beta
blockade therapy though the level of change is significantly less than with placebo.
Beta-1 selective blockers seemed to reduce VO2 max less than the non-selective
beta-blockers, though the significant difference between selective and non-selective
beta-blockers was generally found to be small. There appears to be evidence that
functional capacity is reduced with beta-blockers but there is a lack of agreement in
the extent of the effect. Though researchers have indicated that a decrease in
functional capacity is indicated, the relevance of this information has not indicated
the significance of this change. This change is not indicated to be a practical
difference, enough of a difference to change the work intensity prescribed in the
prescription of exercise for a training regimen when using the American College of
Sports Medicines "Guidelines For Exercise Testing and Prescription".

:METHODS AND PROCEDURES
The meta-analysis technique was used in this study to synthesize the data and
find ifthere is a consensus in the literature as to how beta-blockers affect VO2 max
ofthe healthy population. The procedures ofthis investigation include: (1) collecting
the published research that focused on VO2 max and beta-blockers, (2) developing a
coding form to classify the research based on results ofVO2 max testing, and the
type ofbeta blocker used, and (3) using meta-analysis technique to analyze the data.
The research articles identified for this study were based on an extensive
literature search using WMU library searching system. The major indexes (Medline,
Pub-med, and, ERIC etc.) were employed for the literature search. The key words
used to identify reports for review were: maximal VO2, functional capacity, maximal
oxygen uptake, maximal exercise testing, beta-blockers, and VO2 max testing using
beta-blockers. Searches were limited to: English language published manuscripts,
subjects 18 years and up, and human subjects. More than 100 articles were initially
identified using these key words. There were 39 studies that reported data on VO2
max for subject's taking both beta-blockers and placebo. These studies were relevant
to this investigation because they focused on the effect beta-blockers have on VO2
max. Studies that focused on the effects ofbeta-blockers but did not include VO2
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effects of beta-blockers but, did not include V02 max information were excluded;
likewise studies that were focused on V02 max using different types of equipment,
but did not include beta-blockers were also excluded.
Among the 39 investigations, those containing information on V02 max
testing utilizing methods for both treadmill and a bicycle ergometer were considered
for this study. Use of a metabolic cart to measure V02 consumption during exercise
was a must for each study as V02 is the main measurement used for comparison. The
use of beta-1 selective blockers and non-selective beta-blockers for the studies was
also necessary in order to be considered since beta-blockers are the research variable
of this meta-analysis.
A coding form was developed in order for the inclusion criteria to be
determined (see Appendix B). This form was used to gather data based on the type of
publication, the year the study was published, number of subjects included in each
study, the mean age of the subjects included in the study, and the gender prominence
of the study. The rest of the form dealt with the classification of information relevant
to the meta-analysis such as baseline V02 max and V02 max with beta-blockers.
These classifications were considered important for inclusion into the meta-analysis
since they helped to answer the research question as to the effects of beta-blockers
on V02 max, and were relevant in indicating the compatibility of each article to one
another. These classifications were narrowed down to five major points contained by
the studies utilized in this meta-analysis. The inclusion classifications were: (1)
Normal healthy subjects, (2) Means and standard deviation reported, (3) Subjects
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performing a baseline V02 max test either on treadmill or cycle ergometer, (4)
Repeated measures ofV02 max testing utilizing beta-blockers and placebo, (5)
Subjects assigned in random selection and double blind format. Eleven investigations
met these criteria and were used for the current investigation to answer the research
question. One investigation was later eliminated due ·to its findings using a different
measure for V02 max that was not comparable and could not be converted to the
measures of the other 10 studies.
Tables 1 and 2 (Appendix C) were developed to visually compare the studies
used in this meta-analysis. Table 1 was developed to illustrate the information being
analyzed in this meta-analysis and organized it in a logical order. It provides an
introduction to each study by including the names of the authors for each
investigation, the title and therefore, topic of the investigation, and the measurements
ofV02 max. Maximal oxygen consumption values are provided to reflect the type of
medication used, the dosage used for the study, and/or the characteristics of the
subjects involved. The measurements are recorded to represent the mean V02 max
measurement and standard deviation for the placebo, and medication groups.
Table 2 (Appendix C) was developed to present the results from the studies
according to whether they had no medication, selective beta-blockers, or non
selective beta-blockers. In both Tables, column 1 represents the study# presented so
that they can be easily associated with one another. Table 2 separated the data from
Table I by showing the mean and standard deviation for each of the three distinct
conditions. These conditions included the measurement ofV02 max without
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medication or placebo in column 2, the measurement ofV02 max with beta 1
selective blockers in column 3, and the measurement ofV02 max with non-selective
beta-blockers in column 4. This Table is also used to compare the findings of the
non-medicated V02 max measurements with the two different beta-blocked V02
max measurements. Some values for V02 max with the non-selective beta-blockers
(column 4) compared two different medications (both non-selective beta-blockers)
with very similar results and were therefore, averaged.
Mean scores were then compared to find the difference in V02 max for the
three conditions, non-medicated, selective beta-blockers, and non-selective beta
blockers, and can be found in Table 3 (Appendix C). Standard deviation for the three
conditions was also calculated in Table 3 (Appendix C). The mean and standard
deviation for V02 max was also calculated for only those results in the non
medicated column that also had a result in the selective beta-blocker column in Table
4 (Appendix C). Likewise in Table 5 (Appendix C), the mean and standard deviation
for V02 max without medication was also calculated for only those results in the
non-medicated column that also had a result in the non-selective beta-blocker
column. This was relevant since the results for each variable could then be directly
related to the non-medicated measure since some of the non-medicated measures did
not have a result for either selective beta-blockers, or non- selective beta-blockers.
Percent difference between the V02 max values was then calculated for each variable
as compared with their respective baseline measure in order to show the amount of
change each type of beta-blocker made on their respective group. The amount of
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decrease was calculated by subtracting the medication mean value from the non
medication mean value.
The measurement of the means of V02 max collected in Table 3 were
compared to check for a statistical difference. A series of t-tests were used to test
whether statistical differences exist among the three different conditions.

RESULTS AND DISCUSSION
Results
Results indicate little difference in regards-to the over-all means
(using all ofthe non-medicated condition measures) over the three
conditions. The mean ofthe non-medicated condition was_46.5 mlkt 1 min- 1
±10.03, while the mean for sel�ctive beta-blockers was 46.2 mlkg- 1min- 1 ±
9.56, and the mean for the non-selective beta-blockers-was 44.3 mlkg-1.min- 1
± 938 (Table 3, Appendix C). Table 4· (Appendix C) depicts the averaged
V02 max measure for only those non-medicated conditions that also had V02
max measures for the selective beta-blocker condition and compares those
studies. The measure ofthe non-medicated condition using this parameter
wa3 49.7 mlkg- 1n;i.in- 1 ± 10.07. The measure for the selective beta-blocker
condition divided into the non-medicated condition measure was 7 % lower
than the non-medicated condition, with a difference of3.5 mlkg- 1min- 1 (1
· MET). This compares to a 1% decrease with the same calculation using the
mean for all ofthe·non-medicated condition result and a 0.5 mlkg-'-min- 1
difference (Table 3). Table 5 (Appendix C) depicts the averaged V02 max
measures for only those non-medicated conditions that also had V(h max
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was 48.7 ± 10.98 mlkg-1.min-1. The measure for the non-selective beta-blocker
condition was 9% lower than the non-medicated, with a difference of 4.44 mlkg1.min-1 (1.27 METs). This compares to a 5% decrease with the same calculation using
the mean for all of the non-medicated condition results, and a 2.2 mlkf 1 .min-1
difference from the over-all results (Table 3).
The large standard deviation in the three measurements indicates a wide
variation around the mean, and is consistent in all conditions. This indicates that
when tests resulted in a high score in the non-medicated group, the test scores were
also high in the medicated groups. In contrast when test scores were low in the non
medicated group, the scores for the medicated group were also low. The standard
deviation indicates the span of fitness of the individuals included in each of the
conditions. The similarity in the standard deviation between conditions indicates the
response to beta-blockers was consistent between studies.
The t-test results indicated that there was statistically significant difference
(p<.05) in comparing the placebo condition with selective and non-selective beta
blocker conditions. Although there is a significant difference among the three
conditions, the mean differences were less than two MET in order to show the
empirical importance of the difference based on the ACSM guidelines (Franklin,
Whaley, & Howley, 2000).
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Discussion
The purpose of this meta-analysis was to demonstrate an agreement among
the literature to support the hypothesis (Appendix A) of beta-blockers diminishing
V02 max. The review of literature supported this hypothesis (Appendix A). When
viewed side by side, the means and standard deviations indicate that there was a
diminished value for V02 max in the beta-blocker studies as compared with the
placebo. There is also a comparable difference in the values that were calculated
between the selective beta-blockers and the non-selective beta-blockers. An
explanation for this was brought about in the review of literature where the effects
the two types of medications were explained. Beta-I selective blockers are targeted
primarily at the cardiac muscle and are used to reduce the cardiac contractility of the
heart. Non-selective beta-blockers are targeted at vascular smooth muscle along with
targeting the beta-2 receptors in the lungs. In so doing, they have a diminishing
effect on oxygen uptake in the lungs due to decreased minute ventilation (Peterson,
Whipp, Davis, Huntsman, Brown, & Wasserman, 1983), reducing the amount of
oxygenated blood delivered per minute. It is thought that this has the effect of
reducing the body's ability to do work, by reducing the amount of oxygen available
to be delivered to the musculature of the body. This also has the effect of decreasing
the time to exhaustion, or increasing the rate of fatigue, which limits the amount of
work an individual can do.
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One major determination that needs to be discussed is what should be
considered a significant difference? A more appropriate way to look at this topic
would be to define what is considered a practical difference rather than what is
statistically significant. In other words, how much of a difference indicates a
necessity to change an exercise prescription given by an exercise professional? Or
what difference in absolute V02 requires a change in an exercise prescription?
The American College of Sports Medicine (ACSM), a well-respected
organization of medical professionals has published "The Guidelines for Exercise
Testing and Prescription" for use in both the clinical setting and within the healthy
population. According to the guidelines (Franklin, Whaley, & Howley, 2000), the
prescription of exercise based on exercise testing can be calculated according to
either maximum heart rate achieved during V02 max testing, or maximum Metabolic
Equivalents (MET) achieved. A MET can be defined by the amount of oxygen a
person can take in and utilize during exercise per kilogram of body weight per
minute of time and otherwise referred to as V02 level. One MET is equal to 3.5 ml
of oxygen per kilogram of body weight per minute (1 MET= 3.5 mJ·kg-1.min- 1).
When configuring an exercise prescription for a client, the exercise specialist will
decide to use either MET level achieved, or maximal heart rate achieved during the
test. For maximal heart rate, considering this is an active person, ACSM advises
using a formula, known as the Karvonen formula (Brooks et al. 1996), whereby
subtracting resting heart rate from the maximal heart rate, multiplying by 85%, and
then adding resting heart rate. This value is the target heart rate calculated for the
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client to achieve. When configuring an exercise prescription according to METs, the
exercise specialist will multiply the maximal MET level by 75% for an active
healthy person to give them a target MET level to attain during their exercise
session.
As VO2 max is the variable being reported in this study, MET level is used to
configure an exercise prescription. If two individuals have completed an exercise
test, one result at 10 METs, and the other at nine METs, the exercise professional
will multiply each result by 0.75 to find the appropriate MET level at which the
person will exercise. Use of ACSM's formula for calculating treadmill METs is
completed to give an exercise prescription for speed and grade for each person.
When the work level is calculated for each individual maintaining elevation at eight
percent grade, there is less than one half mile per hour difference in walking speed.
Achieving nine MET's an individual could have a prescription with the speed set at
3.1 mph and percent grade of eight (6.75 METs), and achieving 10 MET's an
individual could have a prescription with the speed set at 3.5 mph and percent grade
of eight (7.5 METs). Four tenths of one mph difference separates each exercise
prescription, and either individual could handle the workload receiving the
cardiovascular benefits they are searching for from either prescription without undue
danger. In configuring the exercise routine to change the elevation used for the
prescription at 3.1 mph would be eight percent for nine MET's, and 9.5% for 10
MET's, again either workload would be tolerable to both individuals. In other words
an exercise prescription for nine MET's as compared to that of 10 MET's would not
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differ profoundly. In another comparison, with a greater difference (two METs), the
speed for an eight MET achievement would result in a speed of2.7 mph at eight
percent grade (six METs) which is almost one mph different than the 10 MET
prescription set at 3.5 mph at eight percent grade (7.5 METs). This individual would
essentially be exceeding the desired exercise intensity by exercising at the max MET
level achieved during VO2 max testing. They would have difficulty in sustaining this
level for any beneficial period oftime and probably not continue at this pace.
Cardiac patients would be endangering themselves to further cardiac events and an
increase in arrhythmia frequency exercising at this level ofexercise. A practical
difference is argued to be two METs rather than one MET.
The results ofthis investigation indicate that there was no substantial
difference in the medicated studies when compared to the over-all result ofthe non
medicated studies (Table 3, Appendix C). A decrease in VO2 max ofless than one
MET was found for the selective beta-blocker group and resulted in a one percent
decrease from the non-medicated condition. The non-selective beta-blocker group
also measured a decrease ofless than one MET and resulted in a five percent
decrease from the non-medicated condition. Further calculation for mean VO2 max
in the non-medication group including only those studies that also included selective
beta-blockers showed a greater difference, (one MET) and a decrease ofseven
percent (Table 4, Appendix C). This calculation was repeated for the non-selective
beta-blocker condition and confirms a decrease in VO2 max for this condition (Table
5, Appendix C). This resulted in a difference of 1.25 METs in this group and is a
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nine percent decrease from the non-medicated group. These results may be thought
to be a statistically significant difference, but as outlined above, it does not represent
a practical difference, being less than the two MET criteria set above.
One other possible reason for the decrease in VO2 max levels for the
medicated studies completed with non-selective beta-·blockers is the arteriovenous
oxygen difference ((a-v)O2 difference). This term is defined as the difference in the
oxygen content of arterial and mixed venous blood. At rest, the pressure of oxygen
(Po2) in the cell fluids of the body measures 40 mm Hg (McArdle et al. 1991). Po2 is
decreased as oxygen is diffused across cell membranes to enter tissues. At rest, blood
leaving the lungs carries approximately 20 ml of oxygen per 100 ml of blood, after
being diffused across the cell membrane; blood carries about 15 ml of oxygen per
100 ml of blood (Brooks et. al, 1996; McArdle et al. 1991). Therefore the (a-v)O2
difference at rest is about 4-5 ml of oxygen per I 00 ml of blood. As exercise
intensity increases, (a-v)O2 difference and heart rate increase linearly, with cardiac
output and (a-v)O2 difference accounting for about 50% of the increase in oxygen
consumption for submaximal exercise (Brooks et al. 1996). At maximal exercise,
cardiac output accounts for approximately 75% of the increased oxygen consumption
(Brooks et al. 1996). With the non-selective beta-blockers decreasing the
effectiveness of the beta-2 receptor sites of the lungs and throughout the body, a
decrease in the amount of vasodilatation will be found, and may reduce the amount
of oxygenation of the blood (Brooks et. al, 1996; McArdle et al. 1991). This would
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reduce the (a-v)O2 difference, as the Po2 in the blood would be lower leaving the
lungs, and reduce the amount of oxygen diffusion across the cell membrane.
Cardiac output has been shown to be maintained during exercise in subjects
on beta-blockers. This maintenance has been found to be due to an increase in stroke
volume to compensate for the decrease in heart rate. According to Brooks et al.
(1996), heart rate is the most important variable controlling cardiac output, and
stroke volume can increase is limited, depending on the size of the heart chambers.
Therefore, cardiac output will reach a plateau at some point during maximal exercise
primarily due to the reduction of heart rate caused by beta-blockers. Cardiac output
cannot be increased any further to meet the demand the body has placed on the heart.
This could help explain the decrease in the VO2 max with the selective and non
selective beta-blockers. The combination of decreased cardiac output and decreased
(a-v)02 difference could explain the typically larger VO2 max in selective beta
blockers when compared to non-selective beta-blockers as non-selective beta
blockers interfere with beta-2 receptors. Non-selective beta-blockers effects on beta2 receptor sites decreases their effectiveness reducing the increase in oxygen
consumption and reducing the amount of work the individual can achieve.

CONCLUSION
This investigation was determined to find a consensus agreement in the
literature that there is a decrease in VO2 max with subjects taking beta-blocker
medication. Given the results found in this investigation, this indicates that a
reduction in VO2 max exists for individuals taking beta-blockers regardless oftype,
and would support the hypothesis (Appendix A). The findings were less impressive
when comparing all of the non-medicated condition to the selective beta-blocker, and
non-selective beta-blocker conditions. The findings including the non-medicated
condition that had results for the selective-beta blocker condition were compared to
indicate that there is a greater decrease in VO2 max with medication. The findings
including the non-medicated condition that had results for the non-selective beta
blocker condition were also compared to indicate an even greater decrease in VO2
max. A 1 MET decrease was found for the selective beta-blockers, and a 1.25 MET
decrease was found for the non-selective beta-blockers. These were determined to be
a decrease of 7 %, and 9 % respectively.
Taking into account the use ofVO2 max calculations to configure an exercise
prescription, ACSM guidelines suggest using 75 % ofthe VO2 max to calculate
workload settings. This workload is often measured in terms ofMETs and as
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indicated in this study, would not differ practically with a difference of one MET
from maximal exercise test results. This information leads to the conclusion that
while there is a statistical difference, it is not a practical difference in VO2 max with
subjects prescribed to beta-blocker therapy. The research does suggest a consensus
agreement exists, indicating a decrease in VO2 max with both selective and non
selective beta-blocker therapy when compared with placebo, exhibiting a greater
decrease among the non-selective beta-blockers.

Appendix A

Delimitations
The study was delimited to:
1. Ten research studies targeting investigation of V02 max and subjects taking
placebo, and beta-blockers.
2. The subjects were all normal healthy individuals ranging in age from 18-39
years.
3. V02 max testing was performed with subjects taking beta-blockers and
placebo.
4. Subjects were randomly assigned to medication and control groups.
Limitations
The study was limited to:
1. Research that has been previously reported and the techniques used by the
investigators of those studies.
2. Any sampling problems of the studies used.
3. Uncontrolled variables.
4. Representative ness of the subjects.
5. Generalize ability of the data collected.
6. Compromises to internal and external validity.
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Assumptions
The assumptions in the study were:
1. All research was reported accurately and without bias.
2. All subjects involved in the studies took the medication/placebo as prescribed
by the investigators.
3. All subjects performed maximally on functional capacity tests.
4. All the equipment in the studies were working properly and calibrated
accurately.
5. Environmental influences are unique to each individual.
Hypothesis
There is consensus agreement in the literature that beta-blockers have a negative
effect on V02 max.
Working Definitions
1. V02 Max- The greatest amount of oxygen one can utilize in strenuous
activity. Also known as functional capacity.
2. Beta-Blockers- Medications designed to block the beta-adrenergic receptors of
the body, causing relaxation of smooth muscle tissue. Leads to a decrease in
heart rate and blood pressure.
3. Placebo- Therapy used as a control to mimic medications being studied for
their effect on subjects.

33
4. Cardiac output- The volume of blood that is pumped out of the heart in one
minute's time measured in liters per min (L/min).
5. Stroke Volume- The amount of blood pumped out of the heart per heartbeat
measured in milliliters per beat (ml/beat).
6. Hypertension- Blood pressure elevated above a certain criteria usually
measured at 140 systolic and 90 diastolic measured in millimeters of mercury
(mm Hg).
7. Respiratory Exchange Ratio- Measurement of the ratio of oxygen
consumption and carbon dioxide release during exercise.
8. Training Effect- The ability of the body to adapt physiologically to practice
typically measured through increases in functional capacity.
9. MET- the amount of oxygen the body can utilize per kilogram of body weight
per minute of time (ml"kg-1.min- 1).

AppendixB

Coding Form
1.

__ Study ID number.

2.

Type of publication: __ Journal article, __ Book or books chapter,
__ Conference report, __ Technical report.

3.

__ Year of the publication.

4.

__ Number of subjects in the study.

5.

__ Mean age of the sample.

6.

Predominant gender of the study: __ All male subjects, __ Greater than
50% male subjects, __ Equal number of male and female subjects,
__Greater than 50% female subjects, __ All female subjects, __Not
reported.

7.

Health risk: __ All healthy subjects, __ Predominantly healthy
subjects, __Equal number of healthy and health problem subjects,
__Predominantly health problem subjects, __ all health problem
subjects.

8.

Activity level: __ All sedentary subjects, __ Equal number of
sedentary and active subjects, __ All active subjects, __ not reported.
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9.

Type of data effect size based on: __ Dichotomous, __Means and
standard deviation, __ t-value, __ Chi Square, __ Pollychotomous,
__ Other (specify) _____

10.

__ Baseline VO2 max measurements evaluated. (1= yes, 0= no)

11.

__ Repeated VO2 max measures evaluated with subjects talcing beta
blockers, and placebo. (1= yes, 0= no)

12.

__ Random selection double blind study. (1= yes, 0= no)

13.

__ Washout period allowed for subjects talcing medications. (1= yes, 2=
no)

14.

__ Training period for subjects between baseline measurements and the
end of the study. ( l =yes, 0= no)

APPENDIXC
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#

Authors

Study

l.

Sweeney, M.
Fletcher, B.
Fletcher,G.

Exercise testing and training
with beta-adrenergic blockade:
role of the drug washout period
in "unmasking" a training effect.
The American Heart Journal.
Nov. 1989.

N=
40
12
8
10
10

2.

3.

4.

5.

Anderson, R.
Wilmore,J.
Joyner, M.
Freund, B.
Hartzell,A.
Todd,C.
Ewy,G.

Effects of cardio-selective and
non -selective beta-adrenergic
blockade on the performance of
highly trained runners. The
American journal of Cardiology.
April 26 1985.

Gordon, N.
VanRensburg,J.
Russell, M.
Kawalsky, D.
Celliers, C.
Celliers, C.
Myburgh, D.

Effects of beta I selective
Adrenoceptor blockade on
physiological response to
exercise. British Heart Journal.
July 1985.

Gullistad, L.
Hallen,J.
Gronnerod, 0.
Holme, I.
Sejersted, 0.

The effects of acute vs. chronic
treatment with betaAdrenoceptor blockade on
exercise performance,
hemodynamic and metabolic
parameters in healthy men and
women. British Journal of
Clinical Pharmacology. January
1996.
The effects of Antihypertensive
medication on the physiological
response to maximal exercise
testing. Journal of
Cardiovascular Pharmacology.
1992.

Derman, W.
Sims, R.
Noakes, T.

V02 measures (mlkg-1.min·1)
Med

Control
no
meds

Week
I with
meds

Week 8
with
meds

Week
9 no
meds

Atenolol 50
(Selective)
Atenolol 100
(Selective)

37.8±
2.9
36.0±
1.2

34.7±
3.6
34.2±

1.3

39.4±
2.8
34.1±
2.0

41.5±
2.4
39.2±
1.9

Propanolol
(Nonselective)
Placebo

32.6±
1.2

30.6±
1.7

33.2±
1.8

36.3±
1.8

35.7±
1.9

36.7±
2.1

40.2±
2.6

41.1 ±
2.5

Med
25

Atenolol
(Selective)
Propanolol
(Nonselective)
Placebo

61.6±5.6
56.1±5.0
63.8±4.2

Med
12

36

Atenolol
(Selective)

44.05±4.72

Placebo

44.98±4.85

Med
15

10

Acute betablocker
Chronic
beta-blocker
Placebo
Med
Atenolol
(Selective)
Nifedipine
(Ca+ channel
blocker)
Cilazapril
(ACE
inhibitor)
Placebo

40.3 ± 1.2
39.1± 1.2
42.3±1.6

45.6±5.55
52.7±5.76
50.3±6.10
54.6±7.40
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6.

7.

8.

9.

10.

Joyner, M.
Fruend, B.
Jilka, S.
Hetrick,G.
Martinezz, E.
Ewy,G.
Wilmore,J.

Kalis,J.
Freund, B.
Joyner, M.
Jilka, S.
Nittolo,J.
Wilmore,J.

Bouissou, P.
Galen. F.
Richalet, J.
Lartigue, M.
Devaux, F.
Dubray, C.
Atlan,G.

Effects of bet-blockade on
exercise capacity oftrained and
untrained men: A hemodynamic
comparison. The Journal of
A1111lied Physiology. 1986

Effect of beta-blockade on the
drift in 02 consumption during
prolonged exercise. The Journal
ofA1111lied Physiology. 1988.

Effects ofpropanolol and
pindolol on plasma ANP levels
in humans at rest and during
exercise. The American Journal
ofPhysiology. 1989.

Joyner, M.
Jilka, S.
Taylor, J.
Kalis,J.
Nittolo,J.
Hicks, R.
Lohman, T.
Wilmore,J.

Beta blockade reduces tidaJ
volume during heavy exercise in
trained and untrained men. The
Journal of A1111lied Physiology.
1987.

Gullestad, L
Hallen, J.
Sejersted, 0.

Variable effects ofBAdrenoceptor blockade on
muscle blood flow during
exercise. Acta Physiologica
Scandinavica. 1993.
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Med

Trained subjects

No meds.

63.3±4.4

Untrained
subiects
44.5±5.7

Atenolol
(Selective)
Propanolol
(Nonselective)
Placebo

59.3±5.4

42.6±4.2

56.2±5.1

41.6±3.8

63.3±4.6

44.5±6.0

Med
14

No meds.

54.8±6.7

Atenolol
(Selective)
Propanolol
(Nonselective)
Placebo

50.7±6.7
48.5 ±4.4
54.4±6.4

Meds
9
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Propanolol
(Nonselective)
Pindolol
(Nonselective)
Placebo

42.35±2.05

Med

Trained subjects

Atenolol
(Selective)
Propanolol
(Nonselective)
Placebo

59.8±4.4

Untrained
subjects
47.8±4.6

57.2±3.0

46.3±4.2

64.7±4.3

51.2±4.8

41.67±2.59
41.08±2.59

Med
15

Propanolol
(Nonselective)
Placebo

36.36±.097
40.14±1.40

38

Table 2. Comparison of non beta-blocked V02 max (ml'kg-t.min- 1) with beta-blocked
V02 max consisting of the measurements in all the tables.
V02 max with nonV02 max Without Meds. V02 max with beta 1
selective beta-blockers
selective blocker Meds.
34.7± 3.6
1. 37.8± 2.9
41.5± 2.4

39.4 ± 2.8

36.0 ± 1.2

34.2 ± 1.3

39.2 ± 1.9

34.1 ± 2.0

32.6 ± 1.2

30.6± 1.7

36.3 ± 1.8

33.2 ± 1.8
56.1± 5.0

2.

63.8 ± 4.2

61.6 ± 5.6

3.

44.98 ± 4.85

44.05 ± 4.72

4.

42.3± 1.6

5.

54.6± 7.4

45.6 ± 5.55

6.

63.3± 4.4

59.3± 5.4

56.2± 5.1

44.5 ± 5.7

42.6± 4.2

41.6± 3.8

7.

54.8 ± 6.7

50.7 ± 6.7

48.5 ± 4.4

8.

42.35± 2.05

9.

64.7 ± 4.3

59.8 ± 4.4

Propanolol- 41.08± 2.59
Pindolol- 41.67 ± 2.59
57.2 ± 3.0

51.2 ± 4.8

47.8± 4.6

46.3± 4.2

10. 40.14± 1.4

Chronic- 39.1±1.2
Acute- 40.3± 1.2

36.36± 0.97
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Table 3. Mean and standard deviation data using all VO 2 max
(mlkg-1.min· 1) results for no medication and compared with
selective and non-selective beta-blockers.
VO2no BetaVO2selective
VO2non-selective
blocker
Beta-blocker
Beta-blocker
VO2max
37.8
34.7
41.5

39.4

36

34.2

39.2

34.1

32.6

30.6

36.3

33.2

63.8

61.6

44.98

44.05

42.3

39.7

54.6

45.6

63.3

59.3

56.2

44.5

42.6

41.6

54.8

50.7

48.5

42.35

41.37

64.7

59.8

57.2

51.2

47.8

46.3

40.14
Mean
SD
%ofVO 2
with no Betablocker.
Difference
from no Betablocker.

56.1

46.5
10.04

36.36
46.2
9.56

44.3
9.38

99.3 %

95.3 %

-0.32

-2.19
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Table 4. Mean and standard deviation data comparing VO2 max
(ml"kg-'-min-1) with no beta-blocker to VO2 max with selective beta
blocker.
VO2 max no beta-blocker VO2 max selective betablocker
37.8
VO2 max
34.7
.,

41.5

39.4

36

34.2

39.2

34.1

63.8

61.6

44.98

44.05

54.6

45.6

63.3

59.3

44.5

42.6

54.8

50.7

64.7

59.8

51.2

47.8

Mean

49.7

46.2

SD

10.07

9.59

% of VO2 max with no
beta-blocker.
Difference from no betablocker.

92.9%
-3.54
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Table 5. Mean and standard deviation data comparing VO2 max
(ml"kg-1.min-1) with no beta-blocker to VO 2 max with non-selective
beta-blocker.
VO2 max no beta-blocker VO2 max non-selective
beta-blocker
VO2max
32.6
30.6
36.3

33.2

63.8

56.1

42.3

39.7

63.3

56.2

44.5

41.6

54.8

48.5

42.35

41.37

64.7

57.2

51.2

46.3

40.14

36.36

Mean

48.7

44.3

SD

10.98

8.94

% of VO2 max with no
beta-blocker.
Difference from no betablocker.

90.9%
-4.44
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